CXCL11 and rheumatoid arthritis: The differential baseline expression of selected genes (IL-7R, CXCL11, IL-18, IL-18rap, and MKI67) among the samples (n = 25) was validated by immunostaining experiments, thereby qualifying them as potential predictive markers of response to adalimumab therapy in RA.